Subscribe to news


Being a company involved in R&D and commercialization of innovative biomedical products, HSCI been always paying significant attention to the development of intellectual property and the creation of intangible assets.
This IP, among other things, is used to invest into joint ventures and for licensing.
HSCI Group is actively implementing its patent development policy: as of the end of 2020, 69 patents (34 - Russia, 35 - abroad) have been received.
The number of trademarks registered by the companies of HSCI Group is over 40.

Patent "A method for obtaining myoblasts, usage of gingiva biopsy, drug based on myoblasts for treatment of muscular tissue pathologies and a method for its obtaining"
Patent "A method of producing endothelial cells (variants)"
Patent "A method of preparing pluripotent stem cells"
Patent "A method of nucleic acids delivery into eukaryotic cells"
Patent "Application of histone protein as an inhibitor of adenoviral transduction"
Patent "Codon-optimised recombinant plasmid, stimulation technique for peripheral nerve regeneration, treatment modality for damaged human nerve"
Patent «A method of preparing a pharmaceutical composition for inducing angiogenesis in a tissue, the pharmaceutical composition obtained under this method, and a method of treating human ischemic tissues and / or organs»
Patent "Method of pluripotent cells generation"
Patent "Method of fibroblast-like cells isolation from newborn's umbilical cord"
Patent "VEGF genetic construct" (+ Licensing Agreement,  Appendix)
Patent "Method of cord blood nucleated cells isolation"
Patent "Method of human embryonic stem cells differentiation into endothelial cells"
International Cord Blood Society Sertificate